evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

10 questions · 12 findings · 1 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 1 · 8.3%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 25%Moderate 3 · 25%High 5 · 41.7%

Three infusions of natalizumab (300 mg) vs placebo

Failure to induce remission at 10 weeks · Patients with active Crohn's disease

Three infusions of natalizumab (300 mg) showed no clear difference in failure to induce remission at 10 weeks compared with placebo (high certainty).

2 findings from 1 review

Three infusions of natalizumab (300 mg) vs placebo

Failure to induce clinical response at end of study · Patients with active Crohn's disease

Three infusions of natalizumab (300 mg) showed no clear difference in failure to induce clinical response at 10 weeks compared with placebo (high certainty).

2 findings from 1 review

Three infusions of natalizumab (300 mg) and two infusions of infliximab (5 mg/kg) vs placebo and two infusions of infliximab

Failure to induce clinical remission at end of study · Participants with active Crohn's disease despite current treatment with infliximab

Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in failure to induce clinical remission at week 10 compared with placebo and two infusions of infliximab (moderate certainty).

1 finding from 1 review

Three infusions of natalizumab (300 mg) and two infusions of infliximab (5 mg/kg) vs placebo and two infusions of infliximab

Adverse events up to week 10 · Participants with active Crohn's disease despite current treatment with infliximab

Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in adverse events up to week 10 compared with placebo and two infusions of infliximab (moderate certainty).

1 finding from 1 review

Three infusions of natalizumab (300 mg) and two infusions of infliximab (5 mg/kg) vs placebo and two infusions of infliximab

Withdrawals due to adverse outcomes · Participants with active Crohn's disease despite current treatment with infliximab

Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in withdrawal due to adverse events up to week 10 compared with placebo and two infusions of infliximab (low certainty).

1 finding from 1 review

Three infusions of natalizumab (300 mg) and two infusions of infliximab (5 mg/kg) vs placebo and two infusions of infliximab

Serious adverse events up to week 10 · Participants with active Crohn's disease despite current treatment with infliximab

Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in serious adverse events up to week 10 compared with placebo and two infusions of infliximab (low certainty).

1 finding from 1 review